RxDoctor Payments Data

Randi Katz

Psychiatric/Mental Health · Houston, TXNPI 1952012189

Payments from drug & device makers

$5,591in general payments, 2019–2025

Across 303 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$850
  • Otsuka America Pharmaceutical, Inc.$580
  • Alkermes, Inc.$504
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$437
  • Johnson & Johnson$364
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$5,591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,591 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$9,115
Medicare patients
26
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$33,690
VraylarCariprazine Hcl20$28,556
RexultiBrexpiprazole11$16,323
Aripiprazole29$8,186
Quetiapine Fumarate235$4,576
Fluvoxamine Maleate ErFluvoxamine Maleate18$4,002
Hydroxyzine Hcl42$1,306
Memantine Hcl39$1,067
Fluoxetine Hcl165$921
Mirtazapine70$881
Trazodone Hcl131$842
Bupropion XlBupropion Hcl37$709
Clonazepam73$631
Buspirone Hcl81$611
Escitalopram Oxalate97$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$364$33,69013 claims
AbbVieVraylar$1,068$28,55620 claims
Otsuka America Pharmaceutical, Inc.Rexulti$580$16,32311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →